Volume | 306,057 |
|
|||||
News | - | ||||||
Day High | 1.36 | Low High |
|||||
Day Low | 1.26 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Personalis Inc | PSNL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.35 | 1.26 | 1.36 | 1.36 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,368 | 306,057 | US$ 1.30 | US$ 398,621 | - | 0.8906 - 2.43 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
13:32:07 | 20 | US$ 1.27 | USD |
Personalis Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
63.63M | 50.50M | - | 73.48M | -108.3M | -2.14 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Personalis News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PSNL Price Data
Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.35 | 1.40 | 1.26 | 1.34 | 185,668 | -0.08 | -5.93% |
1 Month | 1.41 | 1.67 | 1.26 | 1.40 | 211,325 | -0.14 | -9.93% |
3 Months | 1.44 | 1.85 | 1.18 | 1.41 | 222,758 | -0.17 | -11.81% |
6 Months | 1.51 | 2.38 | 1.12 | 1.58 | 363,877 | -0.24 | -15.89% |
1 Year | 2.06 | 2.43 | 0.8906 | 1.50 | 353,927 | -0.79 | -38.35% |
3 Years | 22.81 | 28.47 | 0.8906 | 6.43 | 421,817 | -21.54 | -94.43% |
5 Years | 23.70 | 53.46 | 0.8906 | 14.50 | 484,002 | -22.43 | -94.64% |
Personalis Description
Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. |